II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Cash and Cash Equivalents

Last Annual Value

34.97M

3-Year CAGR

-16%

5-Year CAGR

-26%

10-Year CAGR

7%

II

ImageneBio Inc Competitors Analysis of Cash and Cash Equivalents

IMA · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
34.97M
-33.7%-31.5%N/A 
6.21M
-33.1%-38.3%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
38.92M
-37.5%-32.5%-5.3%
10.66M
8.8%-23.9%41.1%
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
15.48M
-30.8%-29.2%-12.7%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
4.31M
106.0%-2.5%66.0%
29.20M
44.4%12.0%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
53.81M
15.7%-17.8%11.8%
58.13M
-5.7%13.8%17.5%
13.15M
-21.4%-41.2%-12.8%
98.05M
213.9%-13.4%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69